The study of GLP1R variants shows associations with cardiometabolic traits and behavioral changes, highlighting indirect effects of GLP1RA on mental health.

American doctors have now discovered the injections put users at 'significantly higher' risk compared to three other common diabetes drugs.

HealthDay News — Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the short term, according to a study published online January ...

The study of more than two million veterans with diabetes details GLP-1 RA use relating to 175 outcomes; without ...

Vendors such as Color Health promise to save employers money by helping workers catch cancer sooner, but these initiatives ...

GLP-1 medications linked to a lower risk of dementia and addiction but higher risk of kidney, pancreatic, and ...

Incretin-mimetic drugs contribute to dramatic weight loss, but this does not solely mean fat loss. In this article, we explore the impact of incretin-mimetic drugs on muscle health and what can be ...

News research shows GLP-1 medications may help treat a wide range of conditions, from addiction and dementia to heart disease ...

The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY ...

Glucagon-like peptide 1 receptor agonists (GLP1RA)—medications for type 2 diabetes and obesity that have recently been making ...

As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has ...

Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform ...